Reviva Pharmaceuticals Holdings, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-12
- Reviva Pharmaceuticals Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Reviva Pharmaceuticals Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-06-30 was $11.13K.
- Reviva Pharmaceuticals Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-03-31 was $61.19K.
- Reviva Pharmaceuticals Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was $89.01K, a 87.60% decline from fiscal 2024.
- Reviva Pharmaceuticals Holdings, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $717.64K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | ||
| 2025-12-31 | $89.01K 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $11.13K 10-Q · filed 2026-08-12 | $72.32K 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $61.19K 10-Q · filed 2026-05-13 | ||
| 2024-12-31 | $717.64K 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |